39%chance
39.0¢ per share
61.0¢ per share
| Price | Shares | Total |
|---|---|---|
| 23¢ | 40 | $9.20 |
| 22¢ | 112.14 | $24.67 |
| 21¢ | 60 | $12.60 |
| 19¢ | 30 | $5.70 |
| 5¢ | 5 | $0.25 |
| 4¢ | 15.24 | $0.61 |
| 3¢ | 337 | $10.11 |
| 2¢ | 805 | $16.10 |
| 1¢ | 2,237.43 | $22.37 |
| Price | Shares | Total |
|---|---|---|
| 56¢ | 10 | $5.60 |
| 88¢ | 40 | $35.20 |
| 89¢ | 5 | $4.45 |
| 94¢ | 7.92 | $7.44 |
| 97¢ | 65.63 | $63.66 |
| 98¢ | 85 | $83.30 |
| 99¢ | 44.95 | $44.50 |
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.